Sterling Biotech Limited reported unaudited standalone earnings results for the first quarter ended June 30, 2018. For the quarter, the company's revenue from operations was INR 836.708 million compared to INR 1,003.671 million for the same period a year ago. Total income was INR 856.024 million compared to INR 1,021.588 million for the same period a year ago. Loss for the period was INR 23,092.013 million compared to INR 1,095.012 million for the same period a year ago. Basic loss per equity share was INR 137.02 against INR 4.02 for the same period a year ago.